There were 1,804 press releases posted in the last 24 hours and 426,647 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image